A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798
This study is recruiting at 13 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Systemic Lupus Erythematosus
- Active Refractory Rheumatoid Arthritis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- October 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- HonorHealth Research and Innovation Institute · Scottsdale, AZ
Colorado · 1
- University of Colorado · Aurora, CO
Florida · 1
- Bioresearch Partner Coral Terrace · South Miami, FL
Louisiana · 1
- University Medical Center New Orleans · New Orleans, LA
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Minnesota · 1
- Mayo Clinic · Rochester, MN
New York · 3
- Northwell Health · Great Neck, NY
- Columbia University Medical Center · New York, NY
- University of Rochester Medical Center · Rochester, NY
Ohio · 3
- Cleveland Clinic Foundation · Cleveland, OH
- MetroHealth Medical Center · Cleveland, OH
- The Metro Health System Main Campus · Cleveland, OH
Washington · 1
- Seattle Rheumatology Associates · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.